The Food and Drug Administration on Tuesday approved Novo Nordisk's Ozempic to treat chronic kidney disease in patients who also have Type 2 diabetes, expanding the use of the wildly popular ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

A Novo Nordisk drug for hypertension and chronic kidney disease has failed a pivotal study, a setback to the Danish pharmaceutical giant’s effort to bring patients a new therapy with potential ...

March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease ... Richard Pratley, MD is a paid Novo Nordisk, Inc. spokesperson.

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Novo Nordisk said the Food and Drug Administration ... disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, the company said Tuesday.

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA's ...

"All chronic kidney disease is progressive. It's a year-on-year, relentless decline in renal function," Stephen Gough, Novo Nordisk's global chief medical officer, said in an interview, referring ...